Spotlight on pomalidomide: could less be more?

Zander, T; Aebi, S; Pabst, T; Renner, C; Driessen, C

Zander, T; Aebi, S; Pabst, T; Renner, C; Driessen, C.

Affiliation

Zander T; Department of Medical Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.
Aebi S; Department of Medical Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.
Pabst T; Department of Medical Oncology, University Hospital Berne, Berne, Switzerland.
Renner C; Onkozentrum Hirslanden, Zurich, Switzerland.
Driessen C; Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

Leukemia ; 31(9): 1987-1989, 2017 09.

Article in En | MEDLINE | ID: mdl-28529311

Subject(s)

Adjuvants, Immunologic/therapeutic use; Multiple Myeloma/drug therapy; Thalidomide/analogs & derivatives; Adjuvants, Immunologic/adverse effects; Adjuvants, Immunologic/economics; Adjuvants, Immunologic/pharmacokinetics; Dexamethasone/administration & dosage; Drug Administration Schedule; Drug Costs; Humans; Survival Analysis; Thalidomide/adverse effects; Thalidomide/economics; Thalidomide/pharmacokinetics; Thalidomide/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Adjuvants, Immunologic / Multiple Myeloma Limits: Humans Language: En Journal: Leukemia Year: 2017 Document type: Article

Fulltext

XML

PubMed Links

Search on Google